Introduction
============

Cervical cancer is a leading cause of cancer-associated mortality among females worldwide. It accounts for 13% of all female cancer cases, with \>500,000 new cases and \~275,000 mortalities occurring annually ([@b1-ol-0-0-5909]). In Sweden, 450 new cases and 150 mortalities occur each year ([@b2-ol-0-0-5909]). According to reports from the organized Swedish Cervical Cancer Screening Program, \~30,000 women exhibit some form of cellular abnormality and require follow-up with colposcopy and biopsy ([@b3-ol-0-0-5909]).

Persistent infection with human papillomavirus (HPV) is the causative agent in cervical cancer ([@b4-ol-0-0-5909]). HPV depends on differentiated keratinocytes; the infection of the squamous epithelia alone is not sufficient for the infection to progress to neoplasia ([@b5-ol-0-0-5909]). The expression of the HPV oncoproteins E6 and E7 is able to inactivate p53 and retinoblastoma proteins, leading to methylation and mutation of the host genome DNA and resulting in the initiation of and progression towards cancer ([@b6-ol-0-0-5909],[@b7-ol-0-0-5909]). The use of high-risk HPV ([@b8-ol-0-0-5909]) testing in primary screening for cervical disease has exhibited a high sensitivity ([@b9-ol-0-0-5909]), but the specificity of this method is low, and thus a follow-up test must be administered prior to treatment ([@b10-ol-0-0-5909]).

The implementation of organized cervical cancer screening programs has reduced the incidence of cervical cancer considerably ([@b11-ol-0-0-5909]). However, several previous studies have demonstrated that conventional cytology has a limited sensitivity (only 50--70%) to detect cervical intraepithelial neoplasia (CIN) ([@b12-ol-0-0-5909],[@b13-ol-0-0-5909]). Liquid-based cytology (LBC) was developed to improve diagnostic reliability ([@b14-ol-0-0-5909]), as it offers the possibility to use the same sample for HPV testing and triage. Such triage is recommended for women with atypical squamous cells of undetermined significance (ASCUS) due to its high sensitivity, but it is not recommended for women with low-grade squamous intraepithelial lesions (LSIL) due to the high prevalence of high-risk HPV in this population, which generally leads to poor specificity ([@b15-ol-0-0-5909]). The low predictive value of HPV testing among females with minor cytological abnormalities may create unnecessary concern among healthy patients and contribute to a significant risk of over-diagnosis and over-treatment. The use of predictive biomarkers is a novel approach to improving the diagnosis and management of patients with LSIL.

MicroRNA (miRNA) is a small, non-coding RNA that is \~22 nucleotides in length. miRNA has an important role in pathological processes, including viral infection and cancer development ([@b4-ol-0-0-5909]). Generally, miRNA negatively regulates gene expression at the post-transcriptional level via transcription inhibition and/or translation suppression ([@b16-ol-0-0-5909]). Previous studies have identified altered miRNA expression profiles in human cervical cancer tissues and cell lines, and several of them, including miRNA (miR)-145, miR-21 and miR-205, are consistently dysregulated in cervical cancer tissue compared with normal cervical tissue ([@b17-ol-0-0-5909]--[@b19-ol-0-0-5909]). In our previous study, it was revealed that miR-205 expression was significantly increased in cervical cancer tissue compared with matched normal cervical tissue, and that miR-205 has an oncogenic role in cervical cancer through the promotion of cell proliferation and migration ([@b20-ol-0-0-5909]). This prompted the further investigation of the potential value and clinical applications of miR-205 in the present study.

Recently, miRNAs were suggested as potential biomarkers for the diagnosis or prognosis of different cancer types, including cervical cancer ([@b21-ol-0-0-5909]--[@b24-ol-0-0-5909]). Due to the requirement for non-invasive detection methods, the majority of the applications focused on serum or plasma samples. For example, serum miR-203 expression was an independent predictive marker for lymph node, peritoneal and distant metastases, and a poor prognosis marker in patients with gastric cancer ([@b8-ol-0-0-5909]). In patients with colorectal cancer, circulating miR-103, miR-720 and miR-372 were potential novel biomarkers: High serum miR-103 expression levels were significantly associated with histological differentiation grade and lymphatic invasion; high serum miR-720 levels were significantly associated with lymph node metastasis; and high miR-372 levels were significantly associated with tumor size, tumor-node-metastasis stage and poorer overall survival ([@b25-ol-0-0-5909],[@b26-ol-0-0-5909]). Downregulation of miR-205 expression in colorectal cancer predicts the risk of lymph node metastasis ([@b27-ol-0-0-5909]). Circulating miR-205 and let-7f together were reported to be diagnostic biomarkers for ovarian cancer ([@b28-ol-0-0-5909]). Serum miR-205 expression was revealed to be significantly downregulated in patients with glioma compared with healthy controls and was a novel and valuable biomarker for the diagnosis of glioma, and a prognostic factor for those with advanced-grade tumors ([@b29-ol-0-0-5909]). Ma *et al* ([@b30-ol-0-0-5909]) reported that upregulated serum miR-205 is a predictive marker for the prognosis of cervical cancer, and Zhao *et al* ([@b31-ol-0-0-5909]) reported that high circulating miR-20a expression levels represent a potential marker for detecting lymph node metastasis in early-stage cervical cancer. However, only a limited number of studies have performed miRNA detection in cervical exfoliated cells ([@b32-ol-0-0-5909],[@b33-ol-0-0-5909]).

The aim of the present study was to investigate whether miR-205 expression may be used as a novel triage approach to predict high-grade CIN in LBC samples from patients attending the population-based Swedish Cervical Cancer Screening Program.

Materials and methods
=====================

### Study population

Between 2008 and 2012, LBC samples were collected from 140 women with squamous intraepithelial lesions or squamous cell carcinoma detected within the framework of the Swedish Cervical Cancer Screening Program in Stockholm, Sweden ([@b34-ol-0-0-5909]). Cervical cells for LBC were obtained from the ectocervix and endocervix of the uterus, preserved in PreservCyt medium (ThinPrep^®^, Hologic, Boxborough, MA, USA) at −20°C, and evaluated at the Department of Clinical Pathology and Cytology, Karolinska University Hospital (Solna-Stockholm, Sweden). Cytological results were categorized according to the Bethesda classification ([@b35-ol-0-0-5909]), with modifications based on Swedish recommendations: Samples with coilocytosis, but without cellular atypia, were classified as 'within normal limits' (WNL), and LSIL included mild dysplasia only. The diagnosis and staging of CIN was based on colposcopy and histology, and grouped into normal histology (WNL), CIN grade 1 (CIN1), CIN grade 2 (CIN2) and CIN2 or worse (CIN2+). Histological information and high-risk-HPV test results were retrieved from the medical and laboratory records at the Karolinska University Hospital.

This study was approved by the Ethical Review Board at Karolinska Institutet (Stockholm, Sweden) and written informed consent was obtained from all participants prior to sample collection.

### RNA extraction

Cervical cells were collected by centrifugation and washed with cold PBS twice, followed by total RNA extraction using the mirVana™ miRNA isolation kit (Thermo Fisher Scientific, Inc., Waltham, MA, USA), all according to the manufacturer\'s protocol. RNA concentrations were measured using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) and stored at −80°C for further use.

### TaqMan RT-qPCR

miR-205 expression was quantified by TaqMan reverse transcription quantitative polymerase chain reaction (RT-qPCR) using the StepOne Plus real-time PCR system (Thermo Fisher Scientific, Inc.). cDNA was synthesized from 100 ng of RNA using the TaqMan miRNA reverse transcription kit (Applied Biosystems; Thermo Fisher Scientific, Inc.). The pre-designed TaqMan assays for miR-205 (ID 000509) and the reference material RNU6B (ID 001093) were purchased from Thermo Fisher Scientific, Inc. ([@b20-ol-0-0-5909]). All reactions were performed in triplicate, according to the manufacturer\'s protocol. The relative expression of miR-205 was normalized to RNU6B and reported as 2^−∆∆Cq^ ([@b36-ol-0-0-5909]).

### HPV DNA detection

HPV testing was performed at Karolinska University Hospital. Briefly, DNA was extracted from the LBC suspensions using the MagNA Pure LC Robot (Roche Diagnostics, Basel, Switzerland). HPV DNA detection and genotyping were carried out using the Linear Array HPV Genotyping test (Roche Diagnostics, Mannheim, Germany) and Cobas 4800 (Roche Diagnostics, Basel, Switzerland), which detects 37 HPV types: High-risk-HPV types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59/68/73, and 82); probable high-risk-HPV types (HPV26, 53, and 66); and low-risk or undetermined-risk HPV types (HPV6, 11, 40, 42, 43, 44, 54, 55, 61, 62, 64, 67, 69, 70, 71, 72, 81, 83, 84, IS39, and CP6108).

### Statistical analysis

Data were entered into Statistica 7.0 (Statsoft, Inc., Tulsa, OK, USA). The difference in miR-205 expression between all HPV-positive and all HPV-negative samples was analyzed using the Mann-Whitney U test. The associations between miR-205 expression levels and diagnoses (including cytology, histology and the final histopathological diagnosis) were analyzed by the Kruskal-Wallis one-way analysis of variance (ANOVA) test. The correlation of miR-205 expression with age was analyzed with the Spearman Rank Order correlation and Pearson\'s χ^2^ test. Sensitivity and specificity calculations were performed using VassarStats online software (<http://vassarstats.net/>). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Cytology, histology, final diagnosis and HPV status

The median age of the 140 females in the study sample was 32.5 years (range, 23--59 years). Of these patients, 123 (123/140, 87.9%) had histological information available, and 115 (115/140, 82.1%) had HPV test results available in the medical and laboratory records at the Karolinska University Hospital. Among the patients with HPV results, 93 were HPV-positive (93/115, 80.9%) and 22 were HPV-negative (22/115, 19.1%) ([Table I](#tI-ol-0-0-5909){ref-type="table"}).

Of the 93 HPV-positive women, only one (no. 43) was infected with a low-risk HPV type (HPV54). Eighty-seven patients were infected with at least one high-risk HPV type, and 43 (43/93, 46.2%) were infected with either HPV16 or 18, the two most common high-risk HPV types ([Table II](#tII-ol-0-0-5909){ref-type="table"}).

### Sensitivity and specificity of high miR-205 expression levels to predict CIN2+ and CIN3+ in LSIL and HSIL

Sensitivity and specificity analyses were performed among patients with LSIL and high-grade squamous intraepithelial lesions (HSIL), based on high miR-205 expression levels and HPV positivity. The specificity of HPV testing to predict the absence of CIN2+ and cervical intraepithelial neoplasia grade 3 or worse (CIN3+) was 0.11 \[95% confidence interval (CI), 0.03--0.30\] and 0.08 (95% CI, 0.02--0.23), respectively, in women with LSIL. The specificity of high miR-205 expression levels was 0.63 (95% CI, 0.42--0.80) and 0.57 (95% CI, 0.40--0.72), which was significantly higher than that of HPV testing. Although positivity for HPV16, HPV18, or HPV16/18 exhibited a higher sensitivity (0.88, 0.96, and 0.85, respectively, to predict CIN2+; 0.83, 0.94, and 0.73, respectively, to predict CIN3+) than high miR-205 expression levels, these values were not statistically significant ([Table III](#tIII-ol-0-0-5909){ref-type="table"}).

Although the specificity of HPV testing to predict CIN3+ in patients with HSIL was lower than that of high miR-205 expression levels (0.16, 95% CI: 0.05--0.37; 0.38, 95% CI, 0.23--0.56, respectively), this trend was also not statistically significant ([Table IV](#tIV-ol-0-0-5909){ref-type="table"}).

The sensitivity of high miR-205 expression to predict CIN2+ and CIN3+ was 0.56 (95% CI, 0.31--0.78) and 0.50 (95% CI, 0.17--0.83), respectively, among patients with LSIL, whereas HPV testing had a corresponding sensitivity of 1.0 (95% CI, 0.78--1) and 1.0 (95% CI, 0.60--1), respectively. Furthermore, when divided by HPV type, the individual sensitivity values (0.33, 0.11 and 0.44 for CIN2+; 0.38, 0.12 and 0.50 for CIN3+) were not higher than those for high miR-205 expression levels; the ANOVA test revealed that the differences between HPV testing and high miR-205 expression levels were not statistically significant ([Table III](#tIII-ol-0-0-5909){ref-type="table"}). Similar results were obtained in the HSIL group, in which the sensitivity of HPV testing to predict CIN2+ and CIN3+ was 0.87 (95% CI, 0.74--0.94) and 0.89 (95% CI, 0.71--0.97), respectively, which was higher than that of high miR-205 expression levels (0.55, 95% CI, 0.43--0.67 for CIN2+ and 0.50, 95% CI, 0.34--0.66 for CIN3+; [Table IV](#tIV-ol-0-0-5909){ref-type="table"}).

### miR-205 expression is not associated with HPV status, but may differ by HPV type

Using the relative quantification method (2^−∆ΔCq^), as normalized to RNU6B, the relative miR-205 expression in all 140 LBC samples was calculated, and the associations between miR-205 expression and HPV positivity in the 115 samples that had this information available were analyzed using the Mann-Whitney U test. No statistically significant difference in miR-205 expression was observed between HPV-positive (n=93) and HPV-negative (n=22) samples (P=0.97; Z-score=0.039; two-tailed), indicating that miR-205 expression was not associated with HPV positivity. Similar results were obtained using the χ^2^ test ([Table V](#tV-ol-0-0-5909){ref-type="table"}). A univariate test for miR-205 expression in all 140 samples revealed significant differences (P=1×10^−6^), indicating the role of an unknown variable. Therefore, the association between miR-205 expression and HPV type, particularly HPV16 and 18, was investigated using the ANOVA Kruskal-Wallis test. Although the mean miR-205 expression levels in HPV18-positive samples (mean value, 18.98; n=9) were higher than those in HPV16-positive samples (mean value, 12.27; n=34), due to small sample size and large variation between samples, they were not statistically significant (P=0.279).

### miR-205 expression and age

Spearman Rank Order correlation analyses did not reveal any significant correlations between miR-205 expression and age (R=−0.0836; P=0.324); similar results were obtained using χ^2^ tests ([Table V](#tV-ol-0-0-5909){ref-type="table"}).

### miR-205 expression and cervical cancer progression

No significant difference between the LSIL and the HSIL group was observed based on cytology diagnosis, histology diagnosis or final histopathological diagnosis (P=0.64, 0.70 and 0.32, respectively), indicating that miR-205 expression alone was not able to distinguish the progression of cervical cancer in LBC samples. Based on the median expression levels of miR-205 in the 140 LBC samples, the correlations between *miR-205* expression and different characteristics, including age, HPV positivity, HPV type, and final histopathological diagnosis were evaluated using a two-tailed χ^2^ test; however, no significant differences were observed ([Table V](#tV-ol-0-0-5909){ref-type="table"}).

Discussion
==========

Cervical cancer develops from well-recognized, pre-malignant forms. The detection of these forms through population-based screening programs is able to reduce the number of cases of cervical cancer dramatically ([@b37-ol-0-0-5909]). However, more robust and reliable molecular markers are required in current screening programs in order to distinguish between lesions with invasive potential and lesions that will spontaneously regress.

miRNAs are well described non-coding RNAs involved in human cancer, which typically negatively regulate gene expression by transcription repression or translation inhibition ([@b38-ol-0-0-5909]). Dysregulated miRNA profiles have been identified in various human cancer types, including cervical cancer ([@b17-ol-0-0-5909],[@b39-ol-0-0-5909]). However, the majority of previous studies were based on tissue samples or serum samples; there is a lack of knowledge concerning miRNA expression in LBC samples. miR-205 is frequently dysregulated in many cancer types and functions as a either a tumor suppressor or an oncogene, depending on the cellular context ([@b20-ol-0-0-5909]). miR-205 expression in tumor tissue or serum is associated with the development and progression of tumors ([@b40-ol-0-0-5909]). Our previous studies revealed that miR-205 is highly expressed in cervical tumor tissue compared with matched normal cervical tissue, and further demonstrated that miR-205 has an oncogenic role by promoting cell proliferation and migration in cervical cancer cells ([@b17-ol-0-0-5909],[@b20-ol-0-0-5909]). In the present study, miR-205 was selected as an example to evaluate the possibility of miRNA detection by RT-qPCR in LBC samples and to assess the potential value of miR-205 in clinical applications.

The preliminary results revealed that high miR-205 expression levels had a significantly higher specificity than HPV testing to predict the absence of CIN2+ or CIN3+ in women with LSIL, whereas the corresponding sensitivities were not significantly different. This demonstrates that there may be promising clinical applications for miR-205 expression. HPV testing is not recommended to triage women with LSIL due to its poor specificity, but this may be improved by the addition of the evaluation of miR-205 expression in these patients.

Certain miRNAs have been associated with HPV infection in cervical cancer. For example, miR-218 was specifically underexpressed in HPV16-positive cervical cancer cell lines, cervical lesions and cancer tissues when compared with HPV-negative C33A cells and normal cervical cells ([@b41-ol-0-0-5909]). Wang *et al* ([@b42-ol-0-0-5909]) revealed that HPV16 E6 expression is regulated via the histone acetyltransferase p300 and reported that increases in the expression of miR-16, miR-25, miR-92a and miR-378, and decreased expression of miR-22, miR-27a, miR-29a and miR-100 may be attributed to the HPV oncoproteins E6 and E7. In the present study, the association between high miR-205 expression and the presence of HPV was also analyzed, but no significant differences were observed, indicating that miR-205 expression is not associated with HPV infection.

In addition, no significant association between *miR-205* expression and cancer stage was detected based on cytology, histology or final histopathological diagnosis. This may indicate that miR-205 expression levels do not increase at specific stages, but may increase continually during cancer progression. To better address this question, analyses are required to be performed on more than one sample from the same patient, on specially paired samples or on series of samples.

The present study cohort was taken from patients attending the population-based organized cervical cancer screening program in Sweden, and the majority of the samples were pre-malignant. However, the majority of the cells in the samples were normal, and thus it was difficult to distinguish if the miR-205 molecules extracted were from abnormal or normal cells. Theoretically, other single-cell-based detection methods, such as *in situ* hybridization ([@b43-ol-0-0-5909],[@b44-ol-0-0-5909]) or microfluidic flow cytometry ([@b45-ol-0-0-5909],[@b46-ol-0-0-5909]) are practical and ideal methods for LBC.

In conclusion, the findings from this screening-based population study revealed that high miR-205 expression levels in patients with LSIL provided statistically higher specificity than HPV testing to predict the absence of CIN2+ and CIN3+. Therefore, the data suggest that miRNA detection in LBC samples may have a potential application as an adjunct to HPV testing in the triage of women with LSIL. Further studies in larger cohorts or testing for a panel of miRNAs is required before recommendations may be suggested.
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ASCUS

:   atypical squamous cells of undetermined significance

CI

:   confidence interval

CIN

:   cervical intraepithelial neoplasia

CIN1

:   cervical intraepithelial neoplasia grade 1

CIN2

:   cervical intraepithelial neoplasia grade 2

CIN2+

:   cervical intraepithelial neoplasia grade 2 or worse

CIN3+

:   cervical intraepithelial neoplasia grade 3 or worse

HPV

:   human papillomavirus

HSIL

:   high-grade squamous intraepithelial lesion

LBC

:   liquid-based cytology

LSIL

:   low-grade squamous intraepithelial lesions

miRNA

:   microRNA

RT-qPCR

:   reverse transcription-quantitative polymerase chain reaction

WNL

:   within normal limits (normal cytology)

###### 

Summary of clinical features of the study sample (N=140).

  Characteristic (N with results available)   N    \%
  ------------------------------------------- ---- -------
  Cytology (N=140)                                 
    WNL                                       18   12.86
    LSIL                                      45   32.14
    HSIL                                      74   52.86
    Cancer                                    3    2.40
  Histology (N=123)                                
    WNL                                       9    7.32
    CIN1                                      35   28.46
    CIN2                                      28   22.76
    CIN3                                      47   38.21
    Cancer                                    4    3.25
  Final histopathological diagnosis (N=140)        
    WNL                                       16   11.43
    CIN1                                      29   20.71
    CIN2                                      44   31.43
    CIN3                                      47   33.57
    Cancer                                    4    2.86
  HPV testing (N=115)                              
    Positive                                  93   80.87
    Negative                                  22   19.13

N, number; WNL, within normal limits (normal cytology); LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion; CIN1, cervical intra-epithelial neoplasia grade 1; CIN2, cervical intra-epithelial neoplasia grade 2; CIN3, cervical intra-epithelial neoplasia grade 3; HPV, human papillomavirus.

###### 

Detailed clinical information and miR-205 expression in 140 patients.

                                                  HPV                            
  ----- ---- --------- -------- -------- -------- ---------- ------------------- --------
  2     37   61.0439   LSIL     CIN1     CIN1     Positive   31                  HR-HPV
  3     30   6.7449    WNL      n.a.     WNL      n.a.                           
  4     29   34.5873   HSIL     CIN3     CIN3     n.a.                           
  5     35   2.2973    HSIL     CIN3     CIN3     n.a.                           
  6     34   19.0510   LSIL     CIN3     CIN3     Positive   16                  HR-HPV
  7     32   23.3276   HSIL     CIN3     CIN3     Positive   16                  HR-HPV
  8     39   25.2251   HSIL     CIN2     CIN2     n.a.                           
  9     41   3.8929    LSIL     CIN1     CIN1     Negative                       
  10    30   3.3291    HSIL     CIN2     CIN2     Positive   18                  HR-HPV
  11    37   20.8132   HSIL     CIN2     CIN2     Positive                       
  12    26   13.9071   HSIL     CIN2     CIN2     Positive   58                  HR-HPV
  13    34   2.4690    HSIL     CIN3     CIN3     Positive   58                  HR-HPV
  14    33   4.7576    HSIL     CIN1     CIN2     n.a.                           
  15    30   29.0087   LSIL     CIN2     CIN2     Positive   39                  HR-HPV
  19    28   1.2505    LSIL     CIN1     CIN1     Positive                       
  20    28   20.1998   HSIL     CIN3     CIN3     Positive   16,31               HR-HPV
  22    43   7.4901    WNL      n.a.     WNL      Negative                       
  23    42   2.2771    LSIL     CIN1     CIN1     Positive   16,52,82            HR-HPV
  24A   59   2.0112    WNL      n.a.     WNL      Negative                       
  24B   25   7.2827    LSIL     CIN2     CIN2     Positive   31,51,73            HR-HPV
  25    27   39.7380   LSIL     CIN2     CIN2     Positive   31,59               HR-HPV
  28    59   17.1738   HSIL     CIN2     CIN2     n.a.                           
  29    43   0.6120    WNL      CIN1     CIN1     Positive   51                  HR-HPV
  30    43   53.3738   HSIL     CIN3     CIN3     n.a.                           
  31    31   12.1099   HSIL     CIN1     CIN2     Negative                       
  32    44   42.0013   HSIL     CIN3     CIN3     Positive   18                  HR-HPV
  33    43   7.4764    HSIL     CIN1     CIN2     Positive   45                  HR-HPV
  34    31   59.1805   HSIL     CIN2     CIN2     Positive                       
  35    26   3.8242    HSIL     CIN1     CIN2     Negative                       
  36    28   19.4811   HSIL     CIN3     CIN3     n.a.       16,51               
  37    27   2.4561    LSIL     CIN1     CIN1     Positive   53,73               HR-HPV
  38    32   1.4752    LSIL     WNL      CIN1     Positive   82                  HR-HPV
  39    26   14.5685   HSIL     WNL      CIN2     Positive   31,56               HR-HPV
  40    30   14.2268   HSIL     CIN3     CIN3     n.a.                           
  41    28   6.1169    HSIL     WNL      CIN2     Negative                       
  42    33   12.0710   HSIL     CIN3     CIN3     n.a.                           
  43    39   3.5259    HSIL     n.a.     CIN2     Positive   54                  LR-HPV
  44    35   10.6758   HSIL     CIN2     CIN2     Positive   16                  HR-HPV
  45    43   7.5600    HSIL     CIN3     CIN3     Positive   56,                 HR-HPV
  46    26   72.3169   LSIL     CIN2     CIN2     Positive   39,51,58,73         HR-HPV
  47    26   41.7024   HSIL     CIN3     CIN3     Positive   16                  HR-HPV
  48    43   22.4166   WNL      n.a.     WNL      Positive                       
  49    45   16.2120   WNL      n.a.     WNL      Positive                       
  50    41   7.5508    WNL      n.a.     WNL      Negative                       
  51    35   7.5375    WNL      n.a.     WNL      Negative                       
  52    26   32.8494   HSIL     CIN3     CIN3     Positive   18,31,51,52,66,68   HR-HPV
  53    39   14.3435   LSIL     CIN1     CIN1     Positive   18,51               HR-HPV
  54    39   8.1765    HSIL     CIN2     CIN2     Negative                       
  55    29   54.1454   HSIL     CIN1     CIN2     Positive   16,33,59            HR-HPV
  56    43   33.0009   HSIL     CIN1     CIN2     Positive   59                  HR-HPV
  57    33   6.3544    HSIL     CIN3     CIN3     n.a.                           
  58    34   3.6957    WNL      n.a.     WNL      Positive   18                  HR-HPV
  59    43   2.4636    HSIL     CIN3     CIN3     Positive   52                  HR-HPV
  60    54   28.7410   WNL      n.a.     WNL      Negative                       
  61    46   18.0521   WNL      n.a.     WNL      Negative                       
  62    27   7.9717    HSIL     CIN2     CIN2     Positive   16                  HR-HPV
  64    51   6.7104    WNL      n.a.     WNL      Negative                       
  65    41   0.7032    HSIL     CIN3     CIN3     Positive   52                  HR-HPV
  66    29   12.8313   HSIL     CIN2     CIN2     n.a.                           
  67    42   6.9052    HSIL     CIN2     CIN2     Positive   16                  HR-HPV
  68    32   1.3904    LSIL     WNL      CIN1     Negative                       
  69    28   0.3772    HSIL     CIN2     CIN2     n.a.                           
  70    47   6.7330    Cancer   Cancer   Cancer   n.a                            
  71    29   7.7228    WNL      CIN1     CIN1     Positive   16                  HR-HPV
  72    28   9.6434    HSIL     CIN2     CIN2     Positive   16                  HR-HPV
  73    26   6.9220    HSIL     CIN2     CIN2     Positive   16,33               HR-HPV
  74    41   7.0546    HSIL     CIN3     CIN3     n.a.                           
  75    32   4.2851    LSIL     CIN2     CIN2     Positive   33,73               HR-HPV
  76    44   11.3330   HSIL     WNL      CIN2     n.a.                           
  78    51   2.6267    WNL      n.a.     WNL      Negative                       
  79    32   8.7506    LSIL     CIN1     CIN1     Positive   73                  HR-HPV
  80    28   1.6829    HSIL     CIN2     CIN2     n.a.                           
  81    30   3.4284    WNL      n.a.     WNL      Negative                       
  82    48   17.9020   LSIL     WNL      CIN1     Positive   16                  HR-HPV
  84    30   13.8683   LSIL     CIN1     CIN1     Positive   33                  HR-HPV
  85    48   6.9998    WNL      n.a.     WNL      Negative                       
  86    31   6.0450    HSIL     CIN3     CIN3     n.a.                           
  87    30   3.0692    HSIL     CIN2     CIN2     n.a.                           
  88    56   12.7754   WNL      n.a.     WNL      Negative                       
  89    28   16.8543   WNL      WNL      WNL      Negative                       
  90    33   2.0479    HSIL     WNL      CIN2     Positive   51                  HR-HPV
  91    27   40.2667   LSIL     CIN1     CIN1     Negative                       
  93    31   28.9839   HSIL     CIN3     CIN3     Positive   HR-HPV not 16,18    HR-HPV
  94    29   45.6632   HSIL     CIN2     CIN2     n.a.                           
  95    37   6.2884    LSIL     CIN1     CIN1     Positive   31,39,56,53         HR-HPV
  97    28   38.5117   HSIL     CIN1     CIN2     Positive   18                  HR-HPV
  98    29   2.4868    HSIL     CIN2     CIN2     Positive   45,51               HR-HPV
  99    28   8.1134    HSIL     CIN1     CIN2     Positive   51                  HR-HPV
  100   31   1.6449    HSIL     CIN3     CIN3     n.a.                           
  101   29   21.7971   HSIL     CIN1     CIN2     Positive   16                  HR-HPV
  111   31   8.9870    HSIL     CIN3     CIN3     n.a.                           
  113   51   7.1208    Cancer   CIN3     CIN3     Positive   16                  HR-HPV
  115   26   5.0528    HSIL     CIN3     CIN3     n.a.                           
  116   45   2.5974    HSIL     n.a.     CIN2     Positive   51,52               HR-HPV
  117   30   8.9810    HSIL     CIN3     CIN3     Positive   16                  HR-HPV
  119   58   8.5443    LSIL     Cancer   Cancer   Positive   18                  HR-HPV
  121   36   0.6870    HSIL     CIN3     CIN3     Positive   51                  HR-HPV
  124   29   3.5774    HSIL     CIN3     CIN3     Positive   16                  HR-HPV
  126   29   10.9771   HSIL     CIN3     CIN3     Positive   31                  HR-HPV
  127   38   0.4523    HSIL     CIN3     CIN3     Negative                       
  129   30   2.6331    HSIL     CIN3     CIN3     Positive   16                  HR-HPV
  130   37   0.1385    HSIL     CIN3     CIN3     Positive   58                  HR-HPV
  132   29   9.6822    HSIL     CIN3     CIN3     Positive   16,45               HR-HPV
  133   30   3.2601    HSIL     CIN3     CIN3     Positive   16                  HR-HPV
  135   28   7.0403    HSIL     CIN3     CIN3     Positive   16,66               HR-HPV
  136   28   16.9954   HSIL     CIN3     CIN3     Positive   18                  HR-HPV
  137   44   0.2899    HSIL     Cancer   Cancer   n.a                            
  138   51   37.3282   HSIL     WNL      CIN2     Positive   16                  HR-HPV
  139   26   42.2245   HSIL     CIN3     CIN3     Positive   16,68               HR-HPV
  140   36   7.2177    HSIL     CIN3     CIN3     Positive   16                  HR-HPV
  141   42   13.0473   HSIL     CIN3     CIN3     Positive   16                  HR-HPV
  142   30   5.8978    HSIL     CIN3     CIN3     Positive   16                  HR-HPV
  143   34   3.6293    LSIL     CIN2     CIN2     Positive   16,52               HR-HPV
  144   31   10.5154   LSIL     CIN2     CIN2     Positive   18,31,58            HR-HPV
  145   27   2.4491    HSIL     CIN3     CIN3     Positive   16                  HR-HPV
  146   44   4.5693    Cancer   CIN3     CIN3     Positive   16                  HR-HPV
  147   30   2.1592    LSIL     CIN2     CIN2     Positive   16,31,33,39         HR-HPV
  148   55   4.4372    HSIL     Cancer   Cancer   n.a                            
  150   23   2.2068    LSIL     CIN1     CIN1     Positive   51                  HR-HPV
  151   34   0.1408    LSIL     CIN1     CIN1     Positive   51                  HR-HPV
  152   40   22.2206   LSIL     CIN1     CIN1     Positive   51,52,82,83         HR-HPV
  153   39   3.6158    LSIL     CIN3     CIN3     Positive   31                  HR-HPV
  155   39   2.4600    LSIL     CIN2     CIN2     Positive   16                  HR-HPV
  156   23   4.3218    LSIL     CIN1     CIN1     Positive   53                  HR-HPV
  157   49   2.9542    LSIL     CIN1     CIN1     Positive   52,73               HR-HPV
  158   47   19.4705   LSIL     CIN1     CIN1     Positive   52                  HR-HPV
  159   47   1.5333    LSIL     CIN3     CIN3     Positive   52                  HR-HPV
  160   23   5.2855    LSIL     CIN1     CIN1     Positive   31,73               HR-HPV
  161   24   1.7701    LSIL     CIN1     CIN1     Positive   59                  HR-HPV
  162   37   8.7852    LSIL     CIN1     CIN1     Positive   68                  HR-HPV
  163   23   0.7902    LSIL     CIN3     CIN3     Positive   16,39,58,73         HR-HPV
  164   33   5.0789    LSIL     CIN1     CIN1     Positive   31                  HR-HPV
  165   39   4.6425    LSIL     CIN1     CIN1     Positive   31                  HR-HPV
  166   23   7.9566    LSIL     CIN3     CIN3     Positive   31                  HR-HPV
  167   23   29.6942   LSIL     CIN1     CIN1     Positive   31,33,53            HR-HPV
  168   44   2.9572    LSIL     CIN1     CIN1     Positive   56                  HR-HPV
  169   25   4.1910    LSIL     CIN1     CIN1     Positive   51                  HR-HPV
  170   34   85.2947   LSIL     CIN3     CIN3     Positive   35                  HR-HPV
  171   23   42.8047   LSIL     CIN2     CIN2     Positive   51                  HR-HPV
  172   38   0.4877    LSIL     CIN3     CIN3     Positive   16                  HR-HPV

HPV, human papillomavirus; LR, low-risk; HR, high-risk; LSIL, low-grade squamous intraepithelial lesion; CIN1, cervical intra-epithelial neoplasia grade 1; WNL, within normal limits; n.a., not applicable; HSIL, high-grade squamous intraepithelial lesion; CIN3, cervical intra-epithelial neoplasia grade 3; CIN2, cervical intra-epithelial neoplasia grade 2; miR, microRNA.

###### 

Overview of the sensitivity and specificity, PPV, NPV and risk of disease in the LSIL group.

  Triage group   Outcome   Test        TP    FP    FN    TN    N    Prevalence (95% CI)   Sensitivity (95% CI)   Specificity (95% CI)   PPV (95% CI)   NPV (95% CI)   PLR (95% CI)    NLR (95% CI)
  -------------- --------- ----------- ----- ----- ----- ----- ---- --------------------- ---------------------- ---------------------- -------------- -------------- --------------- --------------
  LSIL           CIN2+     high        10    10      8   17    45   0.40                  0.56                   0.63                   0.50           0.68           1.50            0.71
                           miR-205                                  (0.26--0.55)          (0.31--0.78)           (0.42--0.80)           (0.28--0.72)   (0.46--0.84)   (0.79--2.85)    (0.40--1.23)
  LSIL           CIN2+     HPV+        18    24      0     3   45   0.40                  1.00                   0.11                   0.43           1.00           1.12            0
                                                                    (0.26--0.55)          (0.78--1.00)           (0.03--0.30)           (0.28--0.59)   (0.31--1.00)   (0.98--1.29)    
  LSIL           CIN2+     HPV16+        6     3   12    23    44   0.41                  0.33                   0.88                   0.67           0.66           2.89            0.75
                                                                    (0.27--0.57)          (0.14--0.59)           (0.69--0.97)           (0.31--0.91)   (0.48--0.80)   (0.83--10.07)   (0.54--1.06)
  LSIL           CIN2+     HPV18+        2     1   16    25    44   0.41                  0.11                   0.96                   0.67           0.61           2.89            0.92
                                                                    (0.27--0.57)          (0.02--0.36)           (0.78--1.00)           (0.13--0.98)   (0.45--0.75)   (0.28--29.51)   (0.78--1.09)
  LSIL           CIN2+     HPV16+18+     8     4   10    22    44   0.41                  0.44                   0.85                   0.67           0.69           2.89            0.66
                                                                    (0.27--0.57)          (0.22--0.69)           (0.64--0.95)           (0.35--0.89)   (0.50--0.83)   (1.02--8.16)    (0.43--1.01)
  LSIL           CIN3+     high          4   16      4   21    45   0.18                  0.50                   0.57                   0.20           0.84           1.16            0.88
                           miR-205                                  (0.09--0.33)          (0.17--0.83)           (0.40--0.72)           (0.07--0.44)   (0.63--0.95)   (0.53--2.54)    (0.42--1.83)
  LSIL           CIN3+     HPV+          8   34      0     3   45   0.18                  1.00                   0.08                   0.19           1.00           1.09            0
                                                                    (0.09--0.33)          (0.60--1.00)           (0.02--0.23)           (0.09--0.35)   (0.31--1.00)   (0.99--1.20)    
  LSIL           CIN3+     HPV16+        3     6     5   30    44   0.18                  0.38                   0.83                   0.33           0.86           2.25            0.75
                                                                    (0.09--0.33)          (0.10--0.74)           (0.66--0.93)           (0.09--0.69)   (0.69--0.95)   (0.71--7.14)    (0.43--1.30)
  LSIL           CIN3+     HPV18+        1     2     7   34    44   0.18                  0.12                   0.94                   0.33           0.83           2.25            0.93
                                                                    (0.09--0.33)          (0.01--0.53)           (0.80--0.99)           (0.02--0.87)   (0.67--0.92)   (0.23--21.89)   (0.71--1.21)
  LSIL           CIN3+     HPV16+18+     4     8     4   28    44   0.18                  0.50                   0.78                   0.33           0.88           2.25            0.64
                                                                    (0.09--0.33)          (0.17--0.83)           (0.60--0.89)           (0.11--0.65)   (0.70--0.96)   (0.89--5.67)    (0.32--1.31)

PPV, positive predictive value; NPV, negative predictive value; LSIL, low-grade squamous intraepithelial lesions; TP, true positive; FP, false positive; FN, false negative; TN, true negative; CI, confidence interval; PLR, positive likelihood ratio; NLR, negative likelihood ratio; N, number; WNL, within normal limits (normal cytology); CIN2+, cervical intra-epithelial neoplasia grade 2 or worse; CIN3+, cervical intra-epithelial neoplasia grade 3 or worse; HPV, human papillomavirus.

###### 

Overview of the sensitivity and specificity, PPV, NPV and risk of disease in the HSIL group.

  Triage group   Outcome   Test        TP    FP    FN    TN    N    Prevalence (95% CI)   Sensitivity (95% CI)   Specificity (95% CI)   PPV (95% CI)   NPV (95% CI)   PLR (95% CI)   NLR (95% CI)
  -------------- --------- ----------- ----- ----- ----- ----- ---- --------------------- ---------------------- ---------------------- -------------- -------------- -------------- --------------
  HSIL           CIN2+     high        41      0   33      0   74   1                     0.55                   n.a.                   1              0              n.a.           n.a.
                           miR-205                                  (0.94--1.00)          (0.43--0.67)                                  (0.89--1.00)   (0--0.13)                     
  HSIL           CIN2+     HPV+        46      0     7     0   53   1                     0.87                   n.a.                   1              0              n.a.           n.a.
                                                                    (0.92--1.00)          (0.74--0.94)                                  (0.90--1.00)   (0--0.44)                     
  HSIL           CIN2+     HPV16+      22      0   29      0   51   1                     0.43                   n.a.                   1              0              n.a.           n.a.
                                                                    (0.91--1.00)          (0.30--0.58)                                  (0.82--1.00)   (0--0.15)                     
  HSIL           CIN2+     HPV18+        5     0   46      0   51   1                     0.10                   n.a.                   1              0              n.a.           n.a.
                                                                    (0.91--1.00)          (0.04--0.22)                                  (0.46--1.00)   (0--0.10)                     
  HSIL           CIN2+     HPV16+18+   27      0   24      0   51   1                     0.53                   n.a.                   1              0              n.a.           n.a.
                                                                    (0.91--1.00)          (0.39--0.67)                                  (0.84--1.00)   (0--0.17)                     
  HSIL           CIN3+     high        20    21    20    13    74   0.54                  0.50                   0.38                   0.49           0.39           0.81           1.31
                           miR-205                                  (0.42--0.66)          (0.34--0.66)           (0.23--0.56)           (0.33--0.65)   (0.23--0.58)   (0.54--1.22)   (0.87--1.96)
  HSIL           CIN3+     HPV+        25    21      3     4   53   0.53                  0.89                   0.16                   0.54           0.57           1.06           0.67
                                                                    (0.39--0.66)          (0.71--0.97)           (0.05--0.37)           (0.39--0.69)   (0.20--0.88)   (0.86--1.32)   (0.15--2.94)
  HSIL           CIN3+     HPV16+      14      8   14    15    51   0.55                  0.50                   0.65                   0.64           0.52           1.44           0.77
                                                                    (0.40--0.69)          (0.31--0.69)           (0.43--0.83)           (0.41--0.82)   (0.33--0.70)   (0.73--2.81)   (0.51--1.16)
  HSIL           CIN3+     HPV18+        3     2   25    21    51   0.55                  0.11                   0.91                   0.60           0.46           1.23           0.98
                                                                    (0.40--0.69)          (0.03--0.29)           (0.70--0.98)           (0.17--0.93)   (0.31--0.61)   (0.22--6.76)   (0.85--1.12)
  HSIL           CIN3+     HPV16+18+   17    10    11    13    51   0.55                  0.61                   0.57                   0.63           0.54           1.40           0.70
                                                                    (0.40--0.69)          (0.41--0.78)           (0.35--0.76)           (0.42--0.80)   (0.33--0.74)   (0.80--2.43)   (0.41--1.18)

PPV, positive predictive value; NPV, negative predictive value; HSIL, high-grade squamous intraepithelial lesions; TP, true positive; FP, false positive; FN, false negative; TN, true negative; CI, confidence interval; PLR, positive likelihood ratio; NLR, negative likelihood ratio; CIN2+, cervical intraepithelial neoplasia grade 2 or worse; CIN3+, cervical intraepithelial neoplasia grade 3 or worse; HPV, human papillomavirus; n.a., not available.

###### 

Correlation of clinical features of LBC samples with miR-205 expression levels.

  Characteristics           All cases   High miR-205 (\>median)   Low miR-205 (\<median)   P-value^[a](#tfn5-ol-0-0-5909){ref-type="table-fn"}^
  ------------------------- ----------- ------------------------- ------------------------ ------------------------------------------------------
  Age (n=140)                                                                              
    \<32.5                  70          39                        31                       0.1763
    \>32.5                  70          31                        39                       
  HPV (n=115)                                                                              
    Positive                93          47                        46                       0.7352
    Negative                22          12                        10                       
  HPV subtypes (n=90)                                                                      
    HPV16, HPV18            43          23                        20                       0.5267
    Non HPV16, non HPV18    47          22                        25                       
  Cytology (n=140)                                                                         
    LSIL                    45          20                        25                       0.3093
    HSIL                    74          40                        34                       
  Histology (n=123)                                                                        
    CIN1                    35          17                        18                       0.8391
    CIN2+                   79          40                        39                       
  Final diagnosis (n=140)                                                                  
    CIN1                    29          11                        18                       0.1657
    CIN2+                   95          50                        45                       

Two-tailed χ^2^ test (without Yates correlation). High or low miR-205 expression based on the median expression level. LBC, liquid-based cytology; HPV, human papillomavirus; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion; CIN1, cervical intra-epithelial neoplasia grade 1; CIN2+, cervical intra-epithelial neoplasia grade 2 or worse.

[^1]: Contributed equally
